Moderna vaccine is effective in 94.5% according to early analysis of Phase 3 COVE Study

  • by

 

Grafika przedstawiająca wirusa w przybliżeniu.

Moderna Inc. said its Covid-19 vaccine candidate (mRNA-1273) was 94.5% effective in a preliminary data analysis from more than 30,000 volunteers. Importantly, vaccine candidate (mRNA-1273) is expected to remain stable at standard refrigerator temperatures (2° to 8°C) for 30 days, therefore it can be distributed using widely available vaccine delivery and storage infrastructure.

https://investors.modernatx.com/news-releases/news-release-details/modernas-covid-19-vaccine-candidate-meets-its-primary-efficacy